Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1486
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 529–540 of 1,486 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

NCT07024615
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting Not applicable Interventional

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NCT05080673
Status at this site: Recruiting
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
45 Years to 70 Years
Enrollment
9,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2065
U.S. locations
478
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Active, not recruiting Phase 2 Interventional

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511
Site status not listed — check the official record
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Active, not recruiting Not applicable Interventional

Imaging-Guided Low Intensity Focused Ultrasound (LIFU)

NCT05467085
Site status not listed — check the official record
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
BX Pulsar 1002
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943
Site status not listed — check the official record
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Interventions
CTX-009, Paclitaxel
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Active, not recruiting No phase listed Observational

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

NCT03270072
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Dexmedetomidine Trial for Effects on Rhythms, Sleep Architecture, and Biomarker Dynamics in Older Adults

NCT07800910
Site status not listed — check the official record
View directory record Official record
Conditions
Sleep, Circadian Rhythm
Interventions
Dexmedetomidine sublingual film, Placebo Sublingual Film
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Active, not recruiting Not applicable Interventional Results available

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

NCT03728985
Site status not listed — check the official record
View directory record Official record
Conditions
Thoracoabdominal Aortic Aneurysm
Interventions
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
19 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT06795412
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
PYX-201, pembrolizumab
Drug
Lead sponsor
Pyxis Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
San Diego, California • Santa Monica, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting Phase 2 Interventional

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

NCT04374305
Status at this site: Recruiting
View directory record Official record
Conditions
Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
Interventions
Brigatinib, Neratinib, Retifanlimab, Bevacizumab
Drug
Lead sponsor
Scott R. Plotkin, MD, PhD
Other
Eligibility
12 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Indianopolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting Phase 2 Interventional

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

NCT06561347
Status at this site: Recruiting
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Zanubrutinib, Bendamustine, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 27, 2026, 12:53 PM EDT
Recruiting Phase 3 Interventional

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262
Status at this site: Recruiting
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions
VX-880, VX-017
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 27, 2026, 12:53 PM EDT

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.